2013 AIChE Annual Meeting

Session: Holistic Product Development: A Journey From Drug Discovery to Clinical Reality

This sessions seeks contributions that link the multiple steps of development and promote the cross-discipline interactions. Holistic product developmet will enable an upstream design guiding development desicions to fullfill clinical needs.

Chair

Richard Schild, Bristol-Myers Squibb

Co-Chairs

Christopher L. Burcham, Eli Lilly and Company
Mary T. Am Ende, Pfizer Global Research and Development
Paul Collins, Eli Lilly

Presentations

03:15 PM

(178a) A Novel Computational Oral Absorption Simulation Tool to Integrate API Crystal Properties and Drug Product Design Attributes to in Vitro and in Vivo Performance
Kazuko Sagawa, Ravi M. Shanker, Rong Li, Sean K. Bermingham, Dan Braido, Filipe Calado, Kaoutar Abbou Oucherif

03:35 PM

(178b) Differential Diagnosis of Primary Hyperparathyroidism and Extent of Progression Through Short-Term Calcium Loading
Christopher R. Christie, Luke E. K. Achenie, Babatunde A. Ogunnaike

03:55 PM

(178c) Polymer Inhibition of Crystal Growth for Improved Drug Solubility
Caitlin Schram, Stephen Beaudoin, Lynne Taylor

04:15 PM

(178d) Experiences in the Corporate-Wide Deployment of Advanced Modeling Technology: Making the Complicated Look Simple, But No Simpler Than That!
Salvador Garcia-Munoz, Paul Schmitz

04:45 PM

(178e) Crystallization of Active Pharmaceutical Ingredient in Drug Product: A Case Study
Wenning Dai

05:05 PM

(178f) Quality By Design in Integrated Processes: From Drug Substance to Drug Product
Marco Gil, Filipe Gaspar, Nuno Matos

05:25 PM

(178g) Concomitant Co-Crystallization On Engineered Surfaces
Xingyi Shi, Shin Yee Wong, Allan S. Myerson, Xiaochuan Yang